A Phase I, Multicenter, Open-Label, Dose-Escalation, Multidose Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non Hodgkin's Lymphoma

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

- Criteria specific to each tumor type:

- For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease.
Must have failed at least 1 prior systemic therapy

- For B-cell non-Hodgkin's lymphoma (B-NHL): Must have failed at least 1 prior
systemic therapy

- Measurable disease criteria by tumor type:

- For ccRCC: At least 1 unidimensional measurable lesion

- For B-NHL: At least 1 bidimensionally measurable lesion

- Prior therapies for advanced/recurrent ccRCC or relapsed/refractory B-NHL or have
become intolerant to a systemic therapy

- Provide archived or fresh tumor tissue for CD70 status. Subjects must be CD70+

- Provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis
is mandatory for at least 5 and a maximum of 10 B-NHL subjects

Exclusion Criteria:

- Prior therapy with an anti-CD70 antibody

- History of severe hypersensitivity reactions to other monoclonal antibodies

- Active or untreated central nervous system lymphoma

- Active infection (viral, bacterial, or fungal)

- Evidence of bleeding diathesis or coagulopathy

- Active autoimmune disease requiring immunosuppressive therapy

- Known current drug or alcohol abuse